Skip to main content
Caplight Logo









PharmaLegacy

PharmaLegacy

Private
ShanghaiHealthcare & Life Scienceshttps://pharmalegacy.com/

Last Round

M&A

Jan 13, 2026

Est. Valuation

$202M

Total Funding Raised

$100M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

PharmaLegacy is a life sciences company that operates as a preclinical contract research organization providing pharmacology services to pharmaceutical and biotech companies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

preclinical CROcontract research organizationCROin vivo pharmacologyanimal modelsIND enabling studiesoutsourced R&Dnon-human primate studiesNHP studiesPK/PDDMPKGLP toxicologydrug discovery servicesin vitro servicesmedical device testingantibody discoverybiomarker services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PharmaLegacy Comparables

Compare PharmaLegacy with similar companies based on industry and business-model similarity.

PharmaLegacy comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
HuaTeng Biotechnology
81%
ZSHK Laboratories Limited
78%
Beijing Lingfu Biotechnology Co., Ltd.
70%

PharmaLegacy Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AJan 13, 2026
Series B ExtensionOct 22, 2021
Series BFeb 1, 2021
Series A ExtensionFeb 2, 2019
Series AFeb 1, 2017

PharmaLegacy Investors

Notable investors and investment history

PharmaLegacy investors
InvestorRounds
CICC CapitalSeries B
Suzhou Guofa Venture CapitalSeries B Extension
HongShan Capital Group (HSG)Series B Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 13, 2026

    $202M round led by Shanghai OPM Biosciences

  • Mar 23, 2025

    Monthly visitors grew 621% MoM, reaching 10.1K.

PharmaLegacy Filings

Explore SEC and related filing metadata, where available.

PharmaLegacy filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about PharmaLegacy's valuation, stock price, and market status.

Is PharmaLegacy a public or private company?

PharmaLegacy is a private company.

What is the current stock price of PharmaLegacy?

PharmaLegacy is a private company with no public stock price. No recent secondary market data is available.

How much is PharmaLegacy worth (valuation)?

Valuation information for PharmaLegacy is not publicly available.

Can I buy PharmaLegacy stock?

PharmaLegacy shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was PharmaLegacy's last funding round?

Funding round information for PharmaLegacy is not publicly available.

Who are the main investors in PharmaLegacy?

Investor information for PharmaLegacy is not publicly disclosed.

Will PharmaLegacy IPO soon?

No public IPO plans have been announced for PharmaLegacy.

How can I track PharmaLegacy secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor PharmaLegacy's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersShanghai
Employee Range52
Year Founded2008
Last FundingJan 13, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?